Next Article in Journal
CLIC4 Is a New Biomarker for Glioma Prognosis
Previous Article in Journal
Angiogenesis of Avascular Necrosis of the Femoral Head: A Classic Treatment Strategy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 12
Issue 11
10.3390/biomedicines12112578
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Brief Report

Safety and Tolerability of a Shorter Agalsidase Beta Infusion Time in Patients with Classic or Later-Onset Fabry Disease

by
Dominique P. Germain
1,2,3,*,
Alice Porto Vasconcelos
3,
Lien Tran Thi Phuong
2,
Najya Bedreddine
4,
Mihaela Turcan
3,
Wenting Trang
3 and
Lynda Barache
2
1
Division of Medical Genetics, University of Versailles-St Quentin en Yvelines (UVSQ), Paris–Saclay University, 2 Avenue de la Source de la Bièvre, F-78180 Montigny, France
2
Referral Center for Fabry Disease and Lysosomal Diseases, MetabERN, F-92380 Garches, France
3
Division of Medical Genetics, APHP Paris Saclay University, F-92380 Garches, France
4
Association des Patients de la Maladie de Fabry, F-21160 Perrigny les Dijon, France
*
Author to whom correspondence should be addressed.
Biomedicines 2024, 12(11), 2578; https://doi.org/10.3390/biomedicines12112578
Submission received: 22 September 2024 / Revised: 22 October 2024 / Accepted: 25 October 2024 / Published: 11 November 2024
(This article belongs to the Section Drug Discovery, Development and Delivery)
Versions Notes

Abstract

Background: The multisystem manifestations of Fabry disease can create major challenges in patient care. Although enzyme replacement therapy with recombinant agalsidase beta has demonstrated clinical benefits, the standard fortnightly, multi-hour infusion regimen imposes a substantial burden on patients. Methods: We assessed the safety and feasibility of shortening the agalsidase beta infusion time to 90 min in adult patients with classic or later-onset Fabry disease in the absence of premedication. A total of 39 consecutive adult patients (agalsidase-naïve: n = 7; with significant comorbidities: n = 15) with no recent infusion-associated reactions underwent a total of 85 agalsidase beta infusions in our tertiary reference centre for lysosomal diseases. Each infusion was administered at a constant rate (between 0.78 and 1.17 mg/min, depending on the total dose administered). Results: No adverse events of any type (including discomfort and infusion-associated reactions) were reported during or after infusions. The patients’ vital signs and physical examination remained stable, and patients’ satisfaction was high. Conclusions: Our results suggest that shortening the agalsidase beta infusion time to 90 min is safe and feasible in stably treated adult patients with Fabry disease and no recent infusion-associated reactions.

1. Introduction

Fabry disease (FD, OMIM #301500) is an X-linked genetic metabolic disease caused by pathogenic variants in the GLA gene (HUGO Gene Nomenclature Committee ID: 4296; Gene Entrez: 2717; NCBI reference sequence: NM_000169.3) and thus a deficiency in activity of the lysosomal alpha-galactosidase A (α-Gal A, Enzyme Commission number: EC 3.2.1.22; UniProt ID: P06280). This deficiency results in the progressive accumulation of globotriaosylceramide (Gb3) and its deacylated derivative globotriaosylsphingosine (lyso-Gb3) in the lysosomes of various tissues and organs, leading to multisystem manifestations, such as kidney failure, hypertrophic arrhythmogenic cardiomyopathy, and cerebrovascular events [1,2,3,4]. Starting in 2001, enzyme replacement therapy (ERT) [5,6] has significantly improved the care and lives of people with FD by reducing substrate accumulation and thus slowing disease progression. A pharmacological chaperone, migalastat, has also been approved since 2016 by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as an oral therapy, with its use restricted to patients bearing amenable pathogenic variants of GLA [7].
Although gene-activated agalsidase alfa (Replagal®, Takeda Pharmaceutical, Tokyo, Japan) is administered fortnightly by intravenous infusion over 40–60 min [1,6,8,9,10,11,12,13] at a rate between 0.23 mg/min (if infused in 60 min) and 0.35 mg/min (if infused in 40 min), recombinant agalsidase beta (Fabrazyme®, Sanofi, Framingham, MA, USA) is typically administered intravenously (again fortnightly) over a longer period [5,10,14,15,16,17,18,19,20], typically within 2 h 30 min (0.47 mg/min) but often up to 3.5 h (0.33 mg/min) in clinical practice. The more recently EMA- and FDA-approved pegunigalsidase alfa (Elfabrio®, Chiesi Pharmaceutici, Parma, Italy) [21,22,23,24,25], which could be infused in 60 min (1.17 mg/min) during the extension study of the BALANCE clinical trial upon decision of the investigator, should be administered during a minimal time of 90 min (0.78 mg/min), and only after four mandatory infusions in a hospital setting, per FDA decision.
The European Medicines Agency’s summary of product characteristics (SPC) for agalsidase beta (Fabrazyme®) states that the infusion rate should be no more than 0.25 mg/min (15 mg/h) initially to minimize the potential for infusion-associated reactions (IARs), but can be increased once patient tolerance has been established [26]. Hence, depending on the patient’s bodyweight, the therapeutic dose of ERT may need to be delivered over a long period. However, in the absence of IARs or other adverse events, a lengthy infusion regime poses a significant burden on patients’ quality of life and might reduce treatment adherence and therefore effectiveness. Hence, shortening and optimizing infusion protocols to reduce treatment burden while maintaining safety and effectiveness is an area of ongoing research and clinical interest.
A few research groups have described their attempts to reduce the agalsidase beta infusion time safely and effectively. In 2007, a phase IV double-blind, randomized placebo-controlled trial reported on decreasing the infusion time to 90 min in 51 patients treated with agalsidase beta or placebo. However, all the participants received pretreatment with paracetamol or ibuprofen, and some were given an antihistamine. Twenty-eight of the patients reported mild or moderate IARs [27].
The use of a shortened agalsidase beta infusion protocol was reported in a Spanish series of six cases (five women and a man) [28]. The first four to eight infusions were administered over several hours (at an initial, fixed rate of 0.25 mg/min) but subsequent infusions were gradually shortened to as little as 45 min in a hospital setting. Premedication with 1 g paracetamol was provided, and patients were closely monitored during the infusion. The outcomes were favourable, and only one patient (a woman with a history of allergies) experienced an IAR after the tenth (45-min) infusion. The IAR was treated with antihistamines and corticosteroids [28].
An Italian study reported retrospectively on a stepwise infusion rate escalation protocol in a cohort of 53 patients with FD [29]. The initial, standard infusion duration was as long as 7 h in the heaviest patients. Patients experiencing an IAR were premedicated before subsequent infusions. Fifty-two of the 53 patients were able to move to a shorter infusion, and this duration was below 2 h in 38 patients. The mean ± standard deviation (SD) infusion duration was significantly shorter in previously treated patients than in ERT-naïve patients (100.91 ± 15.14 min vs. 130.71 ± 38.53 min, respectively; p < 0.01) [29].
In 2022, the start of a multicentre Italian prospective study with a dose infusion rate of 15 mg/h for the first four months was described [30]. Patients experiencing an IAR were premedicated before subsequent infusions. During the following four infusions, the infusion rate was increased progressively from 15 to 35 mg/h, giving the shortest infusion time at the end of the sixth month [30]. The study’s results were published in 2024: 25 of the 31 enrolled patients were treatment-naïve, and the other 6 had been switched from agalsidase alfa to agalsidase beta. Only 1 patient experienced a (mild) IAR, and 28 of the patients were seronegative at month 12 [31].
In a report published in 2023, a Japanese post-marketing study described the impact of short (<90 min) infusions versus standard (≥90 min) infusions on various safety variables in children and adults with FD [32]. The presence or absence of premedication was not reported. The incidence of serious adverse events was low (less than 1%) in patients weighing less than 30 kg, and the frequency of such events in given individuals fell over time. The authors concluded that gradual reductions in infusion times may be feasible in patients who tolerate treatment well [32].
Despite these valuable contributions, critical questions persist with regard to the initiation of shorter infusion times. To address these knowledge gaps, we evaluated the tolerability of a shortened infusion time for agalsidase beta in adult ERT-naïve and ERT-experienced patients with classic or later-onset FD. The safety of administering agalsidase beta over a 90-min infusion for all FD patients in the absence of recent infusion associated reaction was the primary objective. Specifically, we assessed clinical variables and patient-reported treatment satisfaction and investigated the feasibility of reducing the infusion duration from 2.0–3.5 h to 90 min in routine clinical care under strict medical supervision in our tertiary referral centre, without premedication in adult patients at various stages of disease progression and severity, in the absence of recent infusion-associated reactions.

2. Patients and Methods

Between March 2023 and May 2024, 39 consecutive adult patients with genetically confirmed FD followed at our European Reference Network (ERN) tertiary centre for lysosomal diseases (www.centre-geneo.com) were offered to benefit from a reduced agalsidase beta infusion time in a routine care setting (90 min as per the summary of product characteristics). Most patients had been treated at-home with historically fortnightly 3.5-h gradually decreased to 2.0-h-long intravenous infusions of agalsidase beta, with the exception of seven patients who were naïve to enzyme replacement therapy. Any ongoing or recent agalsidase beta infusion-associated reaction was an exclusion criterion, as was a medical history of IgE antibodies to agalsidase beta at any time in the patient medical history [33]. Patients under 16 years of age and pregnant or lactating women were not considered for participation.
Baseline characteristics (including age, sex, GLA variant, bodyweight, and medical history of comorbidities) were recorded for each patient (Table 1). For all patients, the infusion duration was set to 90 min (as mentioned in the SPC of agalsidase beta) without the administration of premedication. This was performed in the setting of our tertiary referral centre and, for the seven patients naïve to ERT, under the strict medical supervision of a medical doctor present at the patient’s bedside during the 90 min. Once an infusion had started, the infusion rate was not modified. Vital signs (including body temperature, blood pressure, and resting heart rate) were measured before and after the infusion. Any IARs or other adverse events reported by the patient or the attending healthcare professionals were documented (Table 2).
Descriptive statistics were used to summarize patient demographics, genotype characteristics, infusion parameters, and safety outcomes. Continuous variables were reported as the mean ± SD, mean (range), or the median [interquartile range (IQR)], as appropriate. Categorical variables were expressed as the frequency (percentage). Given the descriptive nature of this study, no formal hypotheses were tested.

3. Results

Thirty-nine consecutive adult patients (21 males and 18 females) bearing 29 different pathogenic GLA variants (Table 2) were scheduled for a hospital visit in routine clinical care. The mean (range) age was 50.4 (24–78), and the mean bodyweight was 73.3 kg. Seven of the 39 patients were ERT-naïve and benefited from constant medical surveillance at their bedside during their infusions. Fifteen patients presented with significant comorbidities: these included end-stage renal disease with the requirement for dialysis or kidney transplantation, a history of stroke and/or transient ischaemic attack, hypertrophic cardiomyopathy, atrial fibrillation, an elevated body weight requiring 105 mg of agalsidase beta (n = 5) or a history of IARs (though not ongoing) (Table 2).
For a total of 85 infusions, the mean dose of agalsidase beta infusion was 70.8 mg, delivered over a mean period of 87.2 min; this yielded a mean infusion rate of 0.83 mg/min. The highest agalsidase beta infusion rate recorded in the setting of our routine regimen was 1.17 mg/min, which corresponds to 105 mg of agalsidase beta infused over 90 min in patients with higher body weight (>95 kg (Table 1). Anecdotally, the ultimate highest agalsidase beta infusion rate was 1.40 mg/min in the three patients who, for various imperative reasons or personal convenience, requested a shorter infusion time under strict reinforced medical supervision (70 mg of agalsidase beta infused over 50 min), without any side effect (Table 2).
All 39 participants tolerated the shorter infusions well, with no reports of adverse events (not even discomfort or IARs) during or following any of the procedures. The vital signs remained stable throughout the infusion process, with no clinically significant changes. The level of patient satisfaction was high (Table 3).

4. Discussion

Our present data on clinical variables and vital signs showed that it was feasible to reduce the agalsidase beta infusion duration to 90 min (as outlined in the summary of product characteristics of agalsidase beta) in routine clinical care, without the need for premedication and based on individual patient requirements. Anecdotally, an infusion time below 90 min was specifically requested by patients in a few imperative cases and then applied under strict medical supervision. Importantly, no adverse events or IARs were reported during or after for the 85 infusions administered, and the patients’ vital signs remained stable.
Although our single-centre case series differed from previous studies in this field in several respects, we confirmed the overall literature findings on the safety and tolerability of shorter agalsidase beta infusions. While we assessed a specific 90-min infusion protocol in most patients, Spanish authors tried to shorten the infusion time even more—to as little as 45 min [28]. Similarly, in the small subset of patients (n = 7) who, for personal convenience or imperative reasons on the day of the infusion, requested it from us, further shortening of the infusion time to either 60 min (n = 4) or 50 min (n = 3) under strict medical supervision (medical doctor present at patient’s bedside) was performed without any adverse event. Although some of the patients studied by Italian colleagues were able to move to infusions lasting between 90 and 120 min, the study’s main focus was the efficacy and safety of a fortnightly infusion regimen of initially up to 7 h (for the heaviest patients) [29] that reflected the standard practice from the time of the clinical development program of agalsidase beta [5]. In contrast, our study sought to explore the feasibility and safety profile of shorter infusion durations, specifically targeting a 90-min infusion regimen. Our present results are also partially or fully in line with several findings of a previous Japanese study [32]. The authors observed a non-significant trend towards fewer adverse events in patients weighing less than 30 kg. Likewise, we did not observe obvious disparities in safety outcomes as a function of the patient’s bodyweight or comorbidities. It is noteworthy that the few published studies on this topic were conducted in distinct populations and settings but provide complementary insights into the safety and feasibility of shorter agalsidase beta infusions durations in FD patients receiving enzyme therapy [31]. Our present findings contribute to the growing body of evidence in favour of moving towards the patient-centred treatment of rare lysosomal disorders, including home-based treatment.
Our study had several strengths. Firstly, we included consecutive (but recent IAR-free) patients, which reduced selection bias. Some of the study participants (n = 7) were agalsidase-naïve, others suffered from advanced FD and/or major comorbidities (such as heart failure and kidney failure), and yet others had a past history of allergic reactions; this heterogeneity illustrated the potential for shortening the infusion time in a real-life patient population. Secondly, premedication was not administered.
Our study also had several limitations. Firstly, the sample size (n = 39 patients) was relatively small. Secondly, the study duration was short; hence, further investigation will be needed to validate the long-term safety of optimized infusion protocols. Thirdly, we did not use a validated questionnaire to assess the patients’ level of satisfaction with the shortened infusion. Interestingly, studies conducted in vitro allow for the identification of relatively stable alpha-galactosidase variants that could be present in patients. Several papers report residual activity of missense variants, which could be useful for predicting outcomes [34,35,36,37]. In the future, longer-term multicentre studies should address these points and explore safety, immunological variables [16], and patient-centred outcomes (including quality of life) in individuals receiving optimized agalsidase beta infusion protocols that, for safety reasons, have been implemented only in our tertiary referral centre for now (http://www.centre-geneo.com) and not yet transitioned to a home care setting.
In conclusion, our results support the safety and feasibility of shortening the agalsidase beta infusion time to 90 min in non-premedicated IAR-free, adult patients at various stages of FD. It should be emphasized that our study population may have been less likely to develop IARs since after eight to twelve administrations of ERT, the likelihood of IARs decreases. However, after more than twenty years of routine administration of agalsidase beta, our study aimed at contributing to optimize regimen, increase flexibility, reduce the treatment burden, improve patient adherence, and ultimately improve the patient-centred management of this complex metabolic disorder [38].

Author Contributions

Conceptualization, D.P.G.; methodology, D.P.G., N.B., W.T.; investigation, A.P.V., L.B., D.P.G., M.T., W.T.; resources, D.P.G.; data curation, A.P.V., D.P.G., L.T.T.P.; writing—original draft preparation, D.P.G.; writing—review and editing, A.P.V., D.P.G., M.T.; supervision, D.P.G. All authors have read and agreed to the published version of the manuscript.

Funding

This research did not receive any specific funding from agencies or organizations in the public, commercial, or not-for-profit sectors.

Institutional Review Board Statement

In line with the French legislation, ethical review and approval is not applicable for this study since it qualifies as non-interventional (Reference Methodology MR-003).

Informed Consent Statement

All eligible patients were invited to participate in the study. Patient consent was waived because the study was non-interventional as per summary of product characteristics (SPC). All patients were free to object to the processing of their personal medical data. The study was conducted in accordance with the Declaration of Helsinki.

Data Availability Statement

All data underlying this publication are available in the article.

Acknowledgments

The authors thank the patients for their participation and Hakima Dahmani, Yé Fan, and Laeticia Tjomb for their contribution to data collection.

Conflicts of Interest

D.P.G. is a consultant for Chiesi, Idorsia, Sanofi, and Takeda. A.P.V., L.T.T.P., N.B., M.T., W.T. and L.B. report no conflicts of interest.

References

  1. Desnick, R.J.; Brady, R.; Barranger, J.; Collins, A.J.; Germain, D.P.; Goldman, M.; Grabowski, G.; Packman, S.; Wilcox, W.R. Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann. Intern. Med. 2003, 138, 338–346. [Google Scholar] [CrossRef]
  2. Germain, D.P. Fabry disease. Orphanet J. Rare Dis. 2010, 5, 30. [Google Scholar] [CrossRef] [PubMed]
  3. Pisani, A.; Pieruzzi, F.; Cirami, C.L.; Riccio, E.; Mignani, R. Interpretation of GFR slope in untreated and treated adult Fabry patients. Nephrol. Dial. Transplant. 2023, 39, 18–25. [Google Scholar] [CrossRef] [PubMed]
  4. Tuttolomondo, A.; Pecoraro, R.; Simonetta, I.; Miceli, S.; Pinto, A.; Licata, G. Anderson-Fabry disease: A multiorgan disease. Curr. Pharm. Des. 2023, 19, 5974–5996. [Google Scholar] [CrossRef] [PubMed]
  5. Eng, C.M.; Guffon, N.; Wilcox, W.R.; Germain, D.P.; Lee, P.; Waldek, S.; Caplan, L.; Linthorst, G.E.; Desnick, R.J. Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry’s disease. N. Engl. J. Med. 2001, 345, 9–16. [Google Scholar] [CrossRef] [PubMed]
  6. Schiffmann, R.; Kopp, J.B.; Austin, H.A., III; Sabnis, S.; Moore, D.F.; Weibel, T.; Balow, J.E.; Brady, R.O. Enzyme replacement therapy in Fabry disease: A randomized controlled trial. JAMA 2001, 285, 2743–2749. [Google Scholar] [CrossRef]
  7. Germain, D.P.; Hughes, D.; Nicholls, K.; Bichet, D.; Giugliani, R.; Wilcox, W.R. Treatment of Fabry’s disease with the pharmacologic chaperone migalastat. N. Engl. J. Med. 2016, 375, 545–555. [Google Scholar] [CrossRef]
  8. Beck, M.; Ramaswami, U.; Hernberg-Ståhl, E.; Hughes, D.A.; Kampmann, C.; Mehta, A.B.; Nicholls, K.; Niu, D.M.; Pintos-Morell, G.; Reisin, R.; et al. Twenty years of the Fabry Outcome Survey (FOS): Insights, achievements, and lessons learned from a global patient registry. Orphanet J. Rare Dis. 2022, 17, 238. [Google Scholar] [CrossRef]
  9. Cybulla, M.; Nicholls, K.; Feriozzi, S.; Linhart, A.; Torras, J.; Vujkovac, B.; Botha, J.; Anagnostopoulou, C.; West, M.L. Renoprotective effect of agalsidase alfa: A long-term follow-up of patients with Fabry disease. J. Clin. Med. 2022, 11, 4810. [Google Scholar] [CrossRef]
  10. Frustaci, A.; Verardo, R.; Galea, N.; Alfarano, M.; Magnocavallo, M.; Marchitelli, L.; Sansone, L.; Belli, M.; Cristina, M.; Frustaci, E.; et al. Long-Term Clinical-Pathologic Results of Enzyme Replacement Therapy in Prehypertrophic Fabry Disease Cardiomyopathy. J. Am. Heart Assoc. 2024, 13, e032734. [Google Scholar] [CrossRef]
  11. Goker-Alpan, O.; Longo, N.; McDonald, M.; Shankar, S.P.; Schiffmann, R.; Chang, P.; Shen, Y.; Pano, A. An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naive to enzyme replacement therapy. Drug Des. Devel. Ther. 2016, 10, 1771–1781. [Google Scholar] [CrossRef] [PubMed]
  12. Hughes, D.; Linhart, A.; Gurevich, A.; Kalampoki, V.; Jazukeviciene, D.; Feriozzi, S.; FOS Study Group. Prompt agalsidase alfa therapy initiation is associated with improved renal and cardiovascular outcomes in a Fabry outcome survey analysis. Drug Des. Devel. Ther. 2021, 15, 3561–3572. [Google Scholar] [CrossRef] [PubMed]
  13. Ramaswami, U.; Beck, M.; Hughes, D.; Kampmann, C.; Botha, J.; Pintos-Morell, G.; West, M.L.; Niu, D.-M.; Nicholls, K.; Giugliani, R. Cardio-Renal Outcomes With Long-Term Agalsidase Alfa Enzyme Replacement Therapy: A 10-Year Fabry Outcome Survey (FOS) Analysis. Drug Des. Devel. Ther. 2019, 13, 3705–3715. [Google Scholar] [CrossRef] [PubMed]
  14. Hilz, M.J.; Marthol, H.; Schwab, S.; Kolodny, E.H.; Brys, M.; Stemper, B. Enzyme replacement therapy improves cardiovascular responses to orthostatic challenge in Fabry patients. J. Hypertens. 2010, 28, 1438–1448. [Google Scholar] [CrossRef] [PubMed]
  15. Hopkin, R.J.; Cabrera, G.H.; Jefferies, J.L.; Yang, M.; Ponce, E.; Brand, E.; Feldt-Rasmussen, U.; Germain, D.P.; Guffon, N.; Jovanovic, A.; et al. Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry. Mol. Genet. Metab. 2023, 138, 106967. [Google Scholar] [CrossRef]
  16. Lenders, M.; Brand, E. Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease. J. Am. Soc. Nephrol. 2018, 29, 2265–2278. [Google Scholar] [CrossRef]
  17. Nowak, A.; Dormond, O.; Monzambani, V.; Huynh-Do, U.; Barbey, F. Agalsidase-beta should be proposed as first line therapy in classic male Fabry patients with undetectable alpha-galactosidase A activity. Mol. Genet. Metab. 2022, 137, 173–178. [Google Scholar] [CrossRef]
  18. Ortiz, A.; Abiose, A.; Bichet, D.G.; Cabrera, G.; Charrow, J.; Germain, D.P.; Hopkin, R.J.; Jovanovic, A.; Linhart, A.; Maruti, S.S.; et al. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase beta: Data from the Fabry Registry. J. Med. Genet. 2016, 53, 495–502. [Google Scholar] [CrossRef]
  19. Politei, J.; Schenone, A.B.; Cabrera, G.; Heguilen, R.; Szlago, M. Fabry disease and enzyme replacement therapy in classic patients with same mutation: Different formulations--different outcome? Clin. Genet. 2016, 89, 88–92. [Google Scholar] [CrossRef]
  20. Wanner, C.; Ortiz, A.; Wilcox, W.R.; Hopkin, R.J.; Johnson, J.; Ponce, E.; Ebels, J.T.; Batista, J.L.; Maski, M.; Politei, J.M.; et al. Global reach of over 20 years of experience in the patient-centered Fabry Registry: Advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community. Mol. Genet. Metab. 2023, 139, 107603. [Google Scholar] [CrossRef]
  21. Germain, D.P.; Linhart, A. Pegunigalsidase alfa a novel pegylated recombinant alpha-galactosidase for the treatment of Fabry disease. Front. Genet. 2024, 15, 1395287. [Google Scholar] [CrossRef] [PubMed]
  22. Hughes, D.; Gonzalez, D.; Maegawa, G.; Bernat, J.A.; Holida, M.; Giraldo, P.; Atta, M.G.; Chertkoff, R.; Alon, S.; Almon, E.B.; et al. Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease. Genet. Med. 2023, 25, 100968. [Google Scholar] [CrossRef] [PubMed]
  23. Linhart, A.; Dostálová, G.; Nicholls, K.; West, M.L.; Tøndel, C.; Jovanovic, A.; Giraldo, P.; Vujkovac, B.; Geberhiwot, T.; Brill-Almon, E.; et al. Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: Results from BRIDGE, a phase 3 open-label study. Orphanet J. Rare Dis. 2023, 18, 332. [Google Scholar] [CrossRef] [PubMed]
  24. Schiffmann, R.; Goker-Alpan, O.; Holida, M.; Giraldo, P.; Barisoni, L.; Colvin, R.B.; Jennette, C.J.; Maegawa, G.; Boyadjiev, S.A.; Gonzalez, D.; et al. Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial. J. Inherit. Metab. Dis. 2019, 42, 534–544. [Google Scholar] [CrossRef]
  25. Wallace, E.L.; Goker-Alpan, O.; Wilcox, W.R.; Holida, M.; Bernat, J.; Longo, N.; Linhart, A.; Hughes, D.A.; Hopkin, R.J.; Tøndel, C.; et al. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: Results from the 2-year randomized phase 3 BALANCE study. J. Med. Genet. 2023, 61, 520–530. [Google Scholar] [CrossRef]
  26. European Medicines Agency. Fabrazyme®. Summary of Product Characteristics. Available online: https://www.ema.europa.eu/en/documents/product-information/fabrazyme-epar-product-information_en.pdf (accessed on 7 November 2024).
  27. Banikazemi, M.; Bultas, J.; Waldek, S.; Wilcox, W.R.; Whitley, C.B.; McDonald, M.; Finkel, R.; Packman, S.; Bichet, D.G.; Warnock, D.G.; et al. Disease Clinical Trial Study Agalsidase-beta therapy for advanced Fabry disease: A randomized trial. Ann. Intern. Med. 2007, 146, 77–86. [Google Scholar] [CrossRef]
  28. Sanchez-Purificacion, A.; Castellano, A.; Gutierrez, B.; Galvez, M.; Diaz, B.; Perez, T.; Arnalich, F. Reduction of agalsidase beta infusion time in patients with fabry disease: A case series report and suggested protocol. Mol. Genet. Metab. Rep. 2021, 27, 100755. [Google Scholar] [CrossRef]
  29. Riccio, E.; Zanfardino, M.; Franzese, M.; Capuano, I.; Buonanno, P.; Ferreri, L.; Amicone, M.; Pisani, A. Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol. Mol. Genet. Genom. Med. 2021, 9, e1659. [Google Scholar] [CrossRef]
  30. Mignani, R.; Pieruzzi, F. Safety of a protocol for reduction of agalsidase beta infusion time in Fabry disease: An Italian multi-centre study. Mol. Genet. Metab. Rep. 2022, 30, 100838. [Google Scholar] [CrossRef]
  31. Mignani, R.; Americo, C.; Aucella, F.; Battaglia, Y.; Cianci, V.; Sapuppo, A.; Lanzillo, C.; Pennacchiotti, F.; Tartaglia, L.; Marchi, G.; et al. Reducing agalsidase beta infusion time in Fabry patients: Low incidence of antibody formation and infusion-associated reactions in an Italian multicenter study. Orphanet J. Rare Dis. 2024, 19, 38. [Google Scholar] [CrossRef]
  32. Lee, C.S.; Tsurumi, M.; Eto, Y. Safety and tolerability of agalsidase beta infusions shorter than 90 min in patients with Fabry disease: Post-hoc analysis of a Japanese post-marketing study. Orphanet J. Rare Dis. 2023, 18, 209. [Google Scholar] [CrossRef] [PubMed]
  33. Bodensteiner, D.; Scott, C.R.; Sims, K.B.; Shepherd, G.M.; Cintron, R.D.; Germain, D.P. Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme. Genet. Med. 2008, 10, 353–358. [Google Scholar] [CrossRef] [PubMed]
  34. Cammisa, M.; Correra, A.; Andreotti, G.; Cubellis, M.V. Fabry_CEP: A tool to identify Fabry mutations responsive to pharmacological chaperones. Orphanet J. Rare Dis. 2013, 8, 111. [Google Scholar] [CrossRef] [PubMed]
  35. Cimmaruta, C.; Citro, V.; Andreotti, G.; Liguori, L.; Cubellis, M.V.; Hay Mele, B. Challenging popular tools for the annotation of genetic variations with a real case, pathogenic mutations of lysosomal alpha-galactosidase. BMC Bioinform. 2018, 19 (Suppl. S15), 433. [Google Scholar] [CrossRef]
  36. Citro, V.; Cammisa, M.; Liguori, L.; Cimmaruta, C.; Lukas, J.; Cubellis, M.V.; Andreotti, G. The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense Mutations. Int. J. Mol. Sci. 2016, 17, 2010. [Google Scholar] [CrossRef]
  37. Lukas, J.; Cimmaruta, C.; Liguori, L.; Pantoom, S.; Iwanov, K.; Petters, J.; Hund, C.; Bunschkowski, M.; Hermann, A.; Cubellis, M.V.; et al. Assessment of Gene Variant Amenability for Pharmacological Chaperone Therapy with 1-Deoxygalactonojirimycin in Fabry Disease. Int. J. Mol. Sci. 2020, 21, 956. [Google Scholar] [CrossRef]
  38. Veldman, B.C.F.; Schoenmakers, D.H.; van Dussen, L.; Datema, M.R.; Langeveld, M. Establishing Treatment Effectiveness in Fabry Disease: Observation-Based Recommendations for Improvement. Int. J. Mol. Sci. 2024, 25, 9752. [Google Scholar] [CrossRef]
Table 1. Patients’ demographics.
Table 1. Patients’ demographics.
    Patients
SexFemale, N = 18 1Male, N = 21 1Overall, N = 39 1
Age 154.83 (13.81) [32, 78]46.52 (11.88) [24, 73]50.36 (13.31) [24, 78]
Weight 166.60 (11.76) [48, 95]78.90 (12.74) [57, 106]73.23 (13.64) [48, 106]
GLA genetic variants
Deletion0/18 (0%)1/21 (4.8%)1/39 (2.6%)
Frameshift0/18 (0%)4/21 (19%)4/39 (10%)
Indel0/18 (0%)1/21 (4.8%)1/39 (2.6%)
Missense15/18 (83%)13/21 (62%)28/39 (72%)
Nonsense3/18 (17%)1/21 (4.8%)4/39 (10%)
Splicing0/18 (0%)1/21 (4.8%)1/39 (2.6%)
Phenotype
Classic17/18 (94%)20/21 (95%)37/39 (95%)
Late-onset1/18 (5.6%)1/21 (4.8%)2/39 (5.1%)
Significant comorbidities6/18 (33%)11/21 (52%)17/39 (44%)
Naïve3/18 (17%)3/21 (14%)6/39 (15%)
Infusions
SexFemale, N = 38 1Male, N = 47 1Overall, N = 85 1
Time (min)86.32 (11.01) [50, 90]87.87 (8.32) [50, 90]87.18 (9.59) [50, 90]
502/38 (5.3%)1/47 (2.1%)3/85 (3.5%)
602/38 (5.3%)2/47 (4.3%)4/85 (4.7%)
9034/38 (89%)44/47 (94%)78/85 (92%)
Dose (mg)66.32 (10.89) [35, 70]74.47 (11.81) [70, 105]70.82 (12.05) [35, 105]
354/38 (11%)0/47 (0%)4/85 (4.7%)
7034/38 (89%)41/47 (87%)75/85 (88%)
1050/38 (0%)6/47 (13%)6/85 (7.1%)
Rate (mg/min)0.79 (0.21) [0, 1]0.86 (0.17) [1, 1]0.83 (0.19) [0, 1]
0.394/38 (11%)0/47 (0%)4/85 (4.7%)
0.7830/38 (79%)37/47 (79%)67/85 (79%)
10/38 (0%)1/47 (2.1%)1/85 (1.2%)
1.172/38 (5.3%)8/47 (17%)10/85 (12%)
1.42/38 (5.3%)1/47 (2.1%)3/85 (3.5%)
1 Mean (SD) [Range]; n/N (%).
Table 2. Summary of vital signs of patients before and after 90-min-infusions of agalsidase beta.
Table 2. Summary of vital signs of patients before and after 90-min-infusions of agalsidase beta.
Patient IDSexPhenotype Weight
(kg)		Dose
(mg)		Time (min)Rate
(mg/
min)		Vitals Before InfusionVitals After InfusionHistory of IAR
Pathogenic VariantAverage Time Since the Start of ERT (Years)BT (°C)BP
(mmHg)		HR
(bpm)		BT (°C)BP
(mmHg)		HR
(bpm)		IAR
P#1MClassicp.G183D2263.570900.7836.4118/867336.5117/8872NoNo
590.7836.8131/827536.1124/8177 No
580.7836.9131/877436.8123/7072 No
P#2FClassicp.C52C867.370900.7836.1106/747636.2110/7574NoNo
P#3FClassicp.W236R26670900.7836.4106/756236.5104/7563NoNo
P#4FClassicp.I91T09070900.7836126/797836.2111/7975NoNo
9070900.7836.1121/687636134/8181No
9070900.7836132/896636.8110/7675No
9070900.7836.3121/856236.3112/7666No
9070900.7836.6111/707536.3127/8882No
9170900.7836.2124/827336.1126/8070No
P#5MClassicp.R227Q76970900.7836.2113/806236.1110/8760NoNo
P#6MClassicp.R112C58070900.7836.5129/938536.9145/9070NoNo
7970900.7836.4106/686836.4126/7877No
7970900.7836.4115/807336.6125/8366No
7970900.7836.4138/887536.6135/8775No
7970900.7836.5118/816736.5126/8066No
7970900.7836.3133/798836.3132/8081No
7870701.0036.6119/847136.4121/8171No
P#7FClassicp.P40L55335900.3937110/58583795/4859NoNo
5470900.7836.4101/475337.3111/6457No
5435900.3936.8113/685736.698/5561No
5470900.7836.9108/489337100/5147No
5435900.393697/566837101/5357No
5470900.7836.5103/48663698/5568No
5535900.3936.6110/515937.194/6152No
5570900.7836.3104/547836107/4969No
5570501.4036.6106/706336.4112/7465No
P#8FClassicp.N34H109570900.7836157/907136.3149/9667NoNo
9670900.7836.2146/806336.1140/8066No
P#9FClassicp.N34H37070900.7836.8114/647336.9118/6879NoNo
P#10FClassicp.D93N07870900.7836.6120/846536.5120/8560NoNo
7570900.7836122/636336.6127/8757No
P#11FClassicp.R220*55770900.7836118/766236.3132/6074NoNo
5770900.7836104/786036.498/4969No
5870900.7836.5105/586036.4121/5360No
P#12MClassicp.D93N08070900.7836142/736136142/7361NoNo
80.570900.7836138/816336.5148/8389No
8070900.7836130/745736139/8059No
8070900.7836.1132/775836138/7859No
8070900.7836.2130/775536.7132/7854No
8470800.8835130/756236.4132/7660No
P#13FClassicp.P40L27070900.7836.6131/636237.1129/7864NoNo
6870900.7836.7125/786336.4150/6458No
6870900.7836.4146/725036.7131/9053No
P#14MClassicp.W262Lfs* 42393105901.1736.2117/897536.5149/9868NoNo
P#15MClassicp.W262Lfs* 4178070900.7836161/756436.1153/8757NoNo
70900.7836.3141/846036.2135/6865No
P#16FClassicp.E358G165570900.7836135/775536.8141/7258NoNo
P#17FLater-onsetp.N215S55670900.7836.3104/646636.6100/6474NoNo
5670900.7836.4109/747936.798/6872No
5670900.783795/667036.988/6465No
5670900.7836.8898/716336.7100/7164No
P#18MLater-onsetp.F113L7106105901.1736.5124/776136.4124/7460NoNo
P#19MClassicp.N264A177470900.7836113/745736.5140/8251NoNo
P#20MClassic 7870900.7836142/845636.1133/11852NoNo
8070900.7836.4149/995436.4153/9355No
7670601.1736.2136/795036.7138/8052No
P#21MClassicp.Q327K2393105901.1736.5131/765236.7137/6253NoNo
93105901.1736139/845335.9148/8556No
P#22MClassicp.A156T77170900.7836.393/726636.194/7565NoNo
P#23MClassicp.G361Rfs*248570900.7836109/845136.398/5748NoNo
P#24MClassicp.W236R106070900.7836.2112/646536.6110/6462NoNo
P#25MClassicp.C382Y*15127070900.7836121/668336.7115/5568NoNo
P#26MClassicp.R100T105770900.7836.4102/666436.5105/6668NoNo
P#27FClassicp.F50L107470601.1736.7124/825736.3123/8159NoNo
70900.7836.6120/776036.7139/8961No
P#28FClassicp.F50L107570900.8836.7124/825736.5125/8056NoNo
Classic 7570900.8837,1110/636236.7120/6561No
P#29FClassicp.C52R166070900.8835,9107/727836.3109/7368YesNo
36.8122/947236.4147/9464No
P#30FClassicp.E358K197470601.1736.2139/847636.3140/8371NoNo
P#31MClassicNA2294.5105901.1736143/937236.5144/9570NoNo
P#32FClassicp.G183D1747.570900.7836.5141/807536.1122/6960NoNo
P#33MClassicp.E358del07870900.7836.2114/675536.1117/7149NoNo
70900.7836.5132/955636.5128/7760No
70900.7836.8142/925836.2144/8565No
70900.7836.4122/705536.4122/7055No
70901.0036.4131/836136.8132/8271No
P#34FClassicp.C202*105770501.4036.5110/696036.3119/7162NoNo
P#35MClassicp.D266E57170501.4036110/898336.2109/7984NoNo
P#36FClassicp.C52R178070900.7836.5121/807836.6123/8175NoNo
P#37MClassicp.R342*167070601.1736.2132/827336.3131/7668NoNo
P#38FClassicp.Q306*156470900.7836.8109/736136.7106/6468NoNo
P#39MClassicp.R112C2294105901.1735.8131/835136.2128/7553NoNo
Abbreviations: acute coronary syndrome (ACS), atrial fibrillation (AF), arterial hypertension (AH), atrioventricular block (AVB), body temperature (BT), blood pressure (BP), chronic kidney disease (CKD), infusion associated reaction (IAR), hypertrophic cardiomyopathy (HCM), heart rate (HR), ST-elevation myocardial infarction (STEMI), and transient ischaemic attack (TIA). IAR included cutaneous rash, pruritus, anaphylaxis, headache, dyspnoea, urticaria, or any other relevant reaction.
Table 3. Physical examination performed and questions asked at each infusion by a medical doctor at the patient’s bedside.
Table 3. Physical examination performed and questions asked at each infusion by a medical doctor at the patient’s bedside.
Patient NumberNaïve to ERT
(0 = No/1 = Yes)		Physical ExaminationQuestions
AnaphylaxisCutaneous RashFeverPruritus During the 90-min InfusionDyspnoea During the 90-min InfusionAsthenia During the 90-min InfusionPatient Satisfied About the Reduced Infusion Time
P#10NoNoNoNoNoNoYes
P#20NoNoNoNoNoNoYes
P#30NoNoNoNoNoNoYes
P#41NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
P#50NoNoNoNoNoNoYes
P#6 NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
0NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
P#70NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
P#80NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
P#91NoNoNoNoNoNoYes
P#101NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
P#11 NoNoNoNoNoNoYes
0NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
P#121NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
P#131NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
P#140NoNoNoNoNoNoYes
P#150NoNoNoNoNoNoYes
P#160NoNoNoNoNoNoYes
P#170NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
P#180NoNoNoNoNoNoYes
P#190NoNoNoNoNoNoYes
P#200NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
P#210NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
P#220NoNoNoNoNoNoYes
P#230NoNoNoNoNoNoYes
P#240NoNoNoNoNoNoYes
P#250NoNoNoNoNoNoYes
P#260NoNoNoNoNoNoYes
P#270NoNoNoNoNoNoYes
P#280NoNoNoNoNoNoYes
P#290NoNoNoNoNoNoYes
P#300NoNoNoNoNoNoYes
P#310NoNoNoNoNoNoYes
P#320NoNoNoNoNoNoYes
P#331NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
NoNoNoNoNoNoYes
P#340NoNoNoNoNoNoYes
P#350NoNoNoNoNoNoYes
P#360NoNoNoNoNoNoYes
P#370NoNoNoNoNoNoYes
P#380NoNoNoNoNoNoYes
P#390NoNoNoNoNoNoYes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Germain, D.P.; Porto Vasconcelos, A.; Tran Thi Phuong, L.; Bedreddine, N.; Turcan, M.; Trang, W.; Barache, L. Safety and Tolerability of a Shorter Agalsidase Beta Infusion Time in Patients with Classic or Later-Onset Fabry Disease. Biomedicines 2024, 12, 2578. https://doi.org/10.3390/biomedicines12112578

AMA Style

Germain DP, Porto Vasconcelos A, Tran Thi Phuong L, Bedreddine N, Turcan M, Trang W, Barache L. Safety and Tolerability of a Shorter Agalsidase Beta Infusion Time in Patients with Classic or Later-Onset Fabry Disease. Biomedicines. 2024; 12(11):2578. https://doi.org/10.3390/biomedicines12112578

Chicago/Turabian Style

Germain, Dominique P., Alice Porto Vasconcelos, Lien Tran Thi Phuong, Najya Bedreddine, Mihaela Turcan, Wenting Trang, and Lynda Barache. 2024. "Safety and Tolerability of a Shorter Agalsidase Beta Infusion Time in Patients with Classic or Later-Onset Fabry Disease" Biomedicines 12, no. 11: 2578. https://doi.org/10.3390/biomedicines12112578

APA Style

Germain, D. P., Porto Vasconcelos, A., Tran Thi Phuong, L., Bedreddine, N., Turcan, M., Trang, W., & Barache, L. (2024). Safety and Tolerability of a Shorter Agalsidase Beta Infusion Time in Patients with Classic or Later-Onset Fabry Disease. Biomedicines, 12(11), 2578. https://doi.org/10.3390/biomedicines12112578

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop